Navigation Links
NeuroAiDTM, a treatment for post-stroke recovery, reduced early cardiovascular events and deaths by half after stroke
Date:10/21/2013

SINGAPORE, Oct. 21, 2013 /PRNewswire/ -- NeuroAiD™, a treatment of post-stroke recovery containing natural extracts, reduces early cardiovascular events and deaths by nearly 50% on top of antiplatelet agents within three months after stroke onset, without an increase in bleeding rate and non-vascular deaths  according to research published online in the journal Stroke[1].  

The CHIMES study is an academic international double-blind placebo-controlled clinical trial in 1099 patients having suffered an ischemic stroke of intermediate severity within 72 hours, treated by NeuroAiD™ or placebo and monitored for 3 months.

Considering the positive effects of NeuroAiD™ on cerebral blood flow and a potential role in "ischemic preconditioning," CHIMES researchers hypothesized that NeuroAiD™ may have an effect on preventing the occurrence of early vascular events after stroke onset. They analyzed a composite outcome consisting of vascular events and vascular deaths, all events being blindly adjudicated. NeuroAiD™ was given on top of secondary prevention therapies like antiplatelet drugs, statins, and antihypertensive and antidiabetics treatments.

As a result the vascular outcome occurred in 16 patients (2.9%) of the NeuroAiD™ group, as opposed to 31 patients (5.6%) in the placebo group (p=0.025). This represents half the rate of early cardiovascular events and deaths, which corresponds to about 27 fewer patients suffering a recurrent vascular event or death per 1000 patients treated over 3 months. 

On the safety side, there was no increase in bleeding and non-vascular deaths, confirming the compound's excellent safety profile, with patients on NeuroAiD™ having fewer adverse events than those in the placebo group.

Prof Marie-Germaine Bousser, former Head of Neurology department in Hopital Lariboisiere in
'/>"/>

SOURCE Chimes Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 InfinityQS International, Inc., the global ... , today announces Infusion Chicago, its 9 th ... held Oct. 9-10, 2014, at the Chicago Marriott ... the necessity for implementing a quality system that ... to gain insight into production processes. Complimentary registrations ...
(Date:8/21/2014)... , Aug. 21, 2014 CVS Caremark Corporation (NYSE: ... applicable Reference Yields and consideration payable in connection with its ... August 7, 2014 for (1) any and all of its ... and (2) up to a maximum amount of its 6.125% ... 5.750% Senior Notes due 2017 (collectively, the "Maximum Tender Offer ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis ... three independent members to its Board of Directors, ... experience of the company, a leading licensed producer ... . Internationally, Bedrocan has 13 years, experience in ... in seven countries, including Canada. ...
Breaking Medicine Technology:InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3
... REGENSBURG, Germany, June 2 The TGF-beta 2,inhibitor ... good safety,and tolerability in the systemic treatment of ... administered,intravenously, showed a clear proof of concept. Patients ... for seven days every other week,as second or ...
... Transplant Congress in Toronto, MIAMI, June 2 ... Departments of Surgery and Pathology at the University ... corroborated the value of,monitoring cell- mediated immunity (CMI) ... regular laboratory assay of cell function,(ImmuKnow(R)/Cylex). Their paper, ...
Cached Medicine Technology:Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma 2Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma 3Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma 4University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 2University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 3University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 4
(Date:8/21/2014)... 21, 2014 DMG Productions announces the ... to broadcast on Monday, August 25, 2014 at 7:00 ... , In this episode, Innovations will go behind-the-scenes ... and improves human performance. Audiences will be amazed by ... spaces by installing and providing access to real musical ...
(Date:8/21/2014)... Raleigh, NC (PRWEB) August 21, 2014 ... proteins produced by Staph bacteria has been used to ... just posted an article on the new research. ... at the University of Western Australia treated mesothelioma ... that it killed the cancer cells while simultaneously stimulating ...
(Date:8/21/2014)... San Luis Obispo, CA (PRWEB) August 21, 2014 ... July/August edition of Current Pedorthics, a bi-monthly publication of the ... the field of pedorthics. , Bunion Bootie ... as an alternative solution for bunion sufferers and their pain. ... be worn in nearly any shoe to eliminate the friction ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 According to a ... Academy of Ophthalmology, environmental factors may outweigh genetics in the ... 42 percent of the world’s population is nearsighted, and this ... , “This is an important finding in the field ... “Not only are we finding better ways to treat ...
(Date:8/21/2014)... Beverly Hills Medical Center of Kuwait is excited to ... a new diagnostic option for measuring tear production levels to ... TearLab is a revolutionary new testing method for dry ... amount of tears a patient produces and take the necessary ... Director at the Kuwait medical center. “The test collects a ...
Breaking Medicine News(10 mins):Health News:Announcing New Episode Airing of Innovations on Monday August 25, 2014 via Discovery Channel 2Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 3Health News:Study Suggests Environmental Factors May Outweigh Genetics When It Comes to Myopia 2Health News:Beverly Hills Kuwait is the First Medical Center in Kuwait with Access to TearLab 2
... ON, Sept. 17 /PRNewswire-FirstCall/ - AlphaRx Inc. ... to developing the next,generation of therapeutic products ... candidate, Streptomycin nanoparticles,will be the subject of ... in,Treatment and Pathogenesis of Mycobacterial Infections" at ...
... Company Serves as a Free Resource to Employees Seeking Senior ... ... the nation,s largest,referral service of senior care options, was recently recognized in ... to when an,employer does not offer eldercare assistance as a part of ...
... genes can work in more powerful and sneaky ways than ... JAK that is closely related to a common cancer-causing gene ... manner. JAK disrupts the activity of an organisms DNA on ... on in an embryos development. , A team from the ...
... Hotel, Washington, D.C.,National and International Health Care Professionals will Convene to ... ... Failure Patients, WASHINGTON, Sept. 17 ... convenes Sunday, September,16, 2007 at the Marriott Wardman Park Hotel in ...
... out of 4 Slept Better on New Sleep Better(TM) ... effort to test the,connection between a new, quality bed ... townspeople of Pillow, Pa. let go of one of ... Sleep Better(TM),Project. Residents of this central Pennsylvania bedroom ...
... 16, 2007 New findings by UT Southwestern Medical ... interferes with the beneficial effects estrogen has on the ... between cholesterol and estrogen in heart disease. , The ... October issue of the journal Nature Medicine , ...
Cached Medicine News:Health News:AlphaRx To Present at 47th Annual ICAAC 2Health News:A Place for Mom, Nation's Largest Senior Care Referral Service, Fills a Gap in Employee Benefits 2Health News:If you think cancer genes are simple, you don't know JAK 2Health News:If you think cancer genes are simple, you don't know JAK 3Health News:If you think cancer genes are simple, you don't know JAK 4Health News:If you think cancer genes are simple, you don't know JAK 5Health News:Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research 2Health News:Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research 3Health News:Pillow, PA's Great American Sleep Better(TM)Project Reports Results 2Health News:Pillow, PA's Great American Sleep Better(TM)Project Reports Results 3Health News:Cholesterol byproduct blocks heart health benefits of estrogen 2Health News:Cholesterol byproduct blocks heart health benefits of estrogen 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: